We are live on
!
Find out more
Royalty Pharma
RPRX
RPRX
378 hedge funds and large institutions have $9.24B invested in Royalty Pharma in 2024 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 161 increasing their positions, 113 reducing their positions, and 48 closing their positions.
New
Increased
Maintained
Reduced
Closed
43% more call options, than puts
Call options by funds: $15.3M | Put options by funds: $10.7M
42% more repeat investments, than reductions
Existing positions increased: 161 | Existing positions reduced: 113
35% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 48
4% more funds holding
Funds holding: 363 → 378 (+15)
8% less capital invested
Capital invested by funds: $10B → $9.24B (-$805M)
11.89% less ownership
Funds ownership: 80.04% → 68.15% (-12%)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
Holders
378
Holders Change
+15
Holders Change %
+4.13%
% of All Funds
5.45%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.1%
New
65
Increased
161
Reduced
113
Closed
48
Calls
$15.3M
Puts
$10.7M
Net Calls
+$4.62M
Net Calls Change
-$3.44M
Top Buyers
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$1.43B |
| 2 |
Swedbank
Stockholm,
Sweden
|
-$154M |
| 3 |
Man Group
London,
United Kingdom
|
-$70.2M |
| 4 |
Goldman Sachs
New York
|
-$66.8M |
| 5 |
SCM
Suvretta Capital Management
New York
|
-$48.3M |
